Similar articles for PMID: 27739123

Year	Number of Results
1986	1
1987	1
1993	1
1994	1
1995	1
1997	1
2000	2
2001	2
2003	4
2004	2
2005	2
2006	1
2007	2
2008	7
2009	4
2010	6
2011	13
2012	13
2013	18
2014	20
2015	19
2016	18
2017	25
2018	20
2019	32
2020	46
2021	42
2022	49
2023	14
2024	1

1

Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis.

Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Puig L, et al. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):213-220. doi: 10.1111/jdv.14007. Epub 2016 Oct 28. J Eur Acad Dermatol Venereol. 2017. PMID: 27739123 Review.

2

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Revicki DA, et al. Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11. Dermatology. 2008. PMID: 18187944 Clinical Trial.

3

The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.

Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. Abrouk M, et al. J Dermatolog Treat. 2017 Sep;28(6):488-491. doi: 10.1080/09546634.2016.1278198. Epub 2017 Jan 18. J Dermatolog Treat. 2017. PMID: 28042711 Clinical Trial.

4

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.

Mattei PL, Corey KC, Kimball AB. Mattei PL, et al. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7. doi: 10.1111/jdv.12106. Epub 2013 Feb 21. J Eur Acad Dermatol Venereol. 2014. PMID: 23425140 Review.

5

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.

Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Elewski BE, et al. J Dermatolog Treat. 2017 Sep;28(6):492-499. doi: 10.1080/09546634.2017.1294727. Epub 2017 Mar 7. J Dermatolog Treat. 2017. PMID: 28266243 Clinical Trial.

6

Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).

Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Hägg D, et al. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):452-6. doi: 10.1111/jdv.12576. Epub 2014 Jun 9. J Eur Acad Dermatol Venereol. 2015. PMID: 24911993

7

Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.

Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M. Norlin JM, et al. Br J Dermatol. 2020 Apr;182(4):965-973. doi: 10.1111/bjd.18361. Epub 2019 Oct 16. Br J Dermatol. 2020. PMID: 31325318

8

Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.

Chaptini C, Quinn S, Marshman G. Chaptini C, et al. Australas J Dermatol. 2016 Aug;57(3):e72-5. doi: 10.1111/ajd.12353. Epub 2015 May 26. Australas J Dermatol. 2016. PMID: 26010650

9

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).

Lacour JP, Bewley A, Hammond E, Hansen JB, Horne L, Paul C, Reich K, Seneschal J, De Simone C, Sohrt A, Augustin M, Pellacani G. Lacour JP, et al. Dermatol Ther (Heidelb). 2020 Oct;10(5):1099-1109. doi: 10.1007/s13555-020-00428-1. Epub 2020 Aug 6. Dermatol Ther (Heidelb). 2020. PMID: 32761560 Free PMC article.

10

Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.

van de Kerkhof PCM, Loewe R, Mrowietz U, Falques M, Pau-Charles I, Szepietowski JC. van de Kerkhof PCM, et al. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):119-126. doi: 10.1111/jdv.15922. Epub 2019 Oct 17. J Eur Acad Dermatol Venereol. 2020. PMID: 31465585 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

302 results

Results by year